Internal appointment at UK MHRA as Ian Hudson named new chief exec
This article was originally published in Scrip
Executive Summary
Ian Hudson has been named the new head of the UK Medicines and Healthcare Products Regulatory Agency. Dr Hudson, currently the MHRA’s licensing director, will succeed Professor Sir Kent Woods when the latter steps down in September after almost 10 years as chief executive of the agency. Dr Hudson is well-known in regulatory and industry circles. He is the UK delegate to the European Medicines Agency’s Committee on Human Medicinal Products (CHMP) and has been the committee’s vice-chairman since October 2012.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.